In the past week, FGEN stock has gone down by -12.90%, with a monthly decline of -27.49% and a quarterly plunge of -46.04%. The volatility ratio for the week is 10.36%, and the volatility levels for the last 30 days are 12.91% for FibroGen Inc The simple moving average for the past 20 days is -20.52% for FGEN’s stock, with a -43.84% simple moving average for the past 200 days.
Is It Worth Investing in FibroGen Inc (NASDAQ: FGEN) Right Now?
The 36-month beta value for FGEN is also noteworthy at 0.89. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for FGEN is 93.80M, and at present, short sellers hold a 5.31% of that float. The average trading volume of FGEN on April 03, 2025 was 3.52M shares.
FGEN) stock’s latest price update
FibroGen Inc (NASDAQ: FGEN) has seen a decline in its stock price by -6.70 in relation to its previous close of 0.31. However, the company has experienced a -12.90% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-02 that SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025.
Analysts’ Opinion of FGEN
Many brokerage firms have already submitted their reports for FGEN stocks, with BofA Securities repeating the rating for FGEN by listing it as a “Underperform.” The predicted price for FGEN in the upcoming period, according to BofA Securities is $2 based on the research report published on August 08, 2023 of the previous year 2023.
FGEN Trading at -35.38% from the 50-Day Moving Average
After a stumble in the market that brought FGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -86.71% of loss for the given period.
Volatility was left at 12.91%, however, over the last 30 days, the volatility rate increased by 10.36%, as shares sank -28.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.44% lower at present.
During the last 5 trading sessions, FGEN fell by -14.63%, which changed the moving average for the period of 200-days by -75.00% in comparison to the 20-day moving average, which settled at $0.3592. In addition, FibroGen Inc saw -46.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FGEN starting from Wettig Thane, who purchase 145,000 shares at the price of $0.35 back on Mar 24 ’25. After this action, Wettig Thane now owns 543,329 shares of FibroGen Inc, valued at $50,663 using the latest closing price.
Schoeneck James A, the Director of FibroGen Inc, purchase 250,000 shares at $0.35 during a trade that took place back on Mar 20 ’25, which means that Schoeneck James A is holding 323,722 shares at $88,000 based on the most recent closing price.
Stock Fundamentals for FGEN
Current profitability levels for the company are sitting at:
- -5.08 for the present operating margin
- 0.47 for the gross margin
The net margin for FibroGen Inc stands at -1.61. The total capital return value is set at -1.85.
Based on FibroGen Inc (FGEN), the company’s capital structure generated -0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -1.89. The debt to equity ratio resting at -0.32. The interest coverage ratio of the stock is -15.79.
Currently, EBITDA for the company is -142.43 million with net debt to EBITDA at -0.16. When we switch over and look at the enterprise to sales, we see a ratio of 1.74. The receivables turnover for the company is 1.02for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.
Conclusion
In summary, FibroGen Inc (FGEN) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
